Drug Detail

Information about AYVAKIT

Generic Name
Avapritinib
IND
BLU-285
Brand Name (US)
AYVAKIT
Manufacturer
Blueprint Medicines
Drug Type
Tyrosine Kinase Inhibitor
Delivery
Oral
Approval Status
Approved for GISTS with PDGFRA exon 18 mutations
Indications
GIST, SM
Overall Strategy
KIT Protein Based
Strategy
Block KIT/PDGFRA
Drug Category
KIT/PDGFRA inhibitor + D842V inhibitor

Avapritinib is FDA approved for treatment of adults with unresectable or metastatic GISTs that have mutations in PDGDFRA exon 18 including the D842V mutation.
It is approved for patients in any line of treatment, for example, 1st line, 2nd line, etc., but it is not approved for adjuvant treatment (preventative).